{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T22:57:01Z","timestamp":1785538621149,"version":"3.56.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,30]],"date-time":"2020-12-30T00:00:00Z","timestamp":1609286400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chest"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.chest.2020.12.027","type":"journal-article","created":{"date-parts":[[2020,12,30]],"date-time":"2020-12-30T11:12:11Z","timestamp":1609326731000},"page":"1902-1912","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["Phase II Investigation of the Efficacy of Antimycobacterial Therapy in Chronic Pulmonary Sarcoidosis"],"prefix":"10.1016","volume":"159","author":[{"given":"Wonder P.","family":"Drake","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Culver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Baughman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc A.","family":"Judson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliott D.","family":"Crouser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Ennis","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory D.","family":"Ayers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tan","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenny","family":"Abel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abena","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Kerrigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Sesay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon R.","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.chest.2020.12.027_bib1","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1164\/ajrccm.160.2.ats4-99","volume":"160","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.chest.2020.12.027_bib2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-019-0096-x","article-title":"Sarcoidosis","volume":"5","author":"Grunewald","year":"2019","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"10.1016\/j.chest.2020.12.027_bib3","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1378\/chest.111.3.623","article-title":"Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy","volume":"111","author":"Gottlieb","year":"1997","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.chest.2020.12.027_bib4","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1183\/09031936.00055213","article-title":"Prediction of relapse after discontinuation of infliximab therapy in severe sarcoidosis","volume":"43","author":"Vorselaars","year":"2014","journal-title":"Eur Respir J"},{"issue":"9030","key":"10.1016\/j.chest.2020.12.027_bib5","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S0140-6736(05)65205-1","article-title":"Mycobacteria and sarcoidosis","volume":"348","author":"Mitchell","year":"1996","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.chest.2020.12.027_bib6","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1007\/s10875-012-9700-5","article-title":"Dual analysis for mycobacteria and propionibacteria in sarcoidosis BAL","volume":"32","author":"Oswald-Richter","year":"2012","journal-title":"J\u00a0Clin Immunol"},{"issue":"5","key":"10.1016\/j.chest.2020.12.027_bib7","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1084\/jem.20040429","article-title":"Mycobacterial catalase-peroxidase is a tissue antigen and target of the adaptive immune response in systemic sarcoidosis","volume":"201","author":"Song","year":"2005","journal-title":"J\u00a0Exp Med"},{"issue":"12","key":"10.1016\/j.chest.2020.12.027_bib8","doi-asserted-by":"crossref","first-page":"8784","DOI":"10.4049\/jimmunol.181.12.8784","article-title":"T\u00a0cell responses to mycobacterial catalase-peroxidase profile a pathogenic antigen in systemic sarcoidosis","volume":"181","author":"Chen","year":"2008","journal-title":"J\u00a0Immunol"},{"issue":"5","key":"10.1016\/j.chest.2020.12.027_bib9","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.rmed.2012.01.012","article-title":"Peripheral blood responses to specific antigens and CD28 in sarcoidosis","volume":"106","author":"Ahmadzai","year":"2012","journal-title":"Respir Med"},{"issue":"3","key":"10.1016\/j.chest.2020.12.027_bib10","first-page":"201","article-title":"Effects of broad-spectrum antimycobacterial therapy on chronic pulmonary sarcoidosis","volume":"30","author":"Drake","year":"2013","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"9","key":"10.1016\/j.chest.2020.12.027_bib11","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1001\/jamadermatol.2013.4646","article-title":"Oral antimycobacterial therapy in chronic cutaneous sarcoidosis: a randomized, single-masked, placebo-controlled study","volume":"149","author":"Drake","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.chest.2020.12.027_bib12","first-page":"5042","article-title":"Resolution of chronic ocular sarcoidosis with antimycobacterial therapy","volume":"1","author":"Richmond","year":"2014","journal-title":"Case Rep Intern Med"},{"key":"10.1016\/j.chest.2020.12.027_bib13","unstructured":"National Institutes of Health Clinical Center. Phase II investigation of antimycobacterial therapy on progressive, pulmonary sarcoidosis. NCT02024555. ClinicalTrials.gov. National Institutes of Health; 2013. Updated July 9, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02024555."},{"issue":"7","key":"10.1016\/j.chest.2020.12.027_bib14","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1164\/rccm.200603-402OC","article-title":"Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement","volume":"174","author":"Baughman","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"10.1016\/j.chest.2020.12.027_bib15","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.9050","article-title":"Operative vs\u00a0nonoperative treatment for atraumatic rotator cuff tears: a trial protocol for the arthroscopic rotator cuff pragmatic randomized clinical trial","volume":"2","author":"Jain","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.chest.2020.12.027_bib16","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jse.2018.10.001","article-title":"Physical therapy versus natural history in outcomes of rotator cuff tears: the Rotator Cuff Outcomes Workgroup (ROW) cohort study","volume":"28","author":"Dickinson","year":"2019","journal-title":"J\u00a0Shoulder Elbow Surg"},{"key":"10.1016\/j.chest.2020.12.027_bib17","series-title":"Multiple Imputation for Nonresponse in Surveys","author":"Rubin","year":"2004"},{"issue":"2","key":"10.1016\/j.chest.2020.12.027_bib18","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1378\/chest.123.2.413","article-title":"Recovery of cell wall-deficient organisms from blood does not distinguish between patients with sarcoidosis and control subjects","volume":"123","author":"Brown","year":"2003","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.chest.2020.12.027_bib19","first-page":"25","article-title":"Prolonged culture for mycobacteria in mediastinal lymph nodes from patients with pulmonary sarcoidosis. A negative study","volume":"21","author":"Milman","year":"2004","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"5","key":"10.1016\/j.chest.2020.12.027_bib20","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1183\/09031936.00156314","article-title":"Negative clinical trials in sarcoidosis: failed therapies or flawed study design?","volume":"44","author":"Moller","year":"2014","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.chest.2020.12.027_bib21","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/00000441-199003000-00002","article-title":"The use of low dose methotrexate in refractory sarcoidosis","volume":"299","author":"Lower","year":"1990","journal-title":"Am J Med Sci"},{"issue":"6","key":"10.1016\/j.chest.2020.12.027_bib22","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.chest.2016.06.005","article-title":"Lung function decline according to clinical course in nontuberculous mycobacterial lung disease","volume":"150","author":"Park","year":"2016","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.chest.2020.12.027_bib23","first-page":"90","article-title":"Endpoints for clinical trials of sarcoidosis","volume":"29","author":"Baughman","year":"2012","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"6","key":"10.1016\/j.chest.2020.12.027_bib24","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1183\/09031936.00060612","article-title":"Established and experimental medical therapy of pulmonary sarcoidosis","volume":"41","author":"Baughman","year":"2013","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.chest.2020.12.027_bib25","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s10875-009-9311-y","article-title":"Mycobacterial ESAT-6 and katG are recognized by sarcoidosis CD4+ T\u00a0cells when presented by the American sarcoidosis susceptibility allele, DRB1\u22171101","volume":"30","author":"Oswald-Richter","year":"2010","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.chest.2020.12.027_bib26","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/1465-9921-11-161","article-title":"Multiple mycobacterial antigens are targets of the adaptive immune response in pulmonary sarcoidosis","volume":"11","author":"Oswald-Richter","year":"2010","journal-title":"Respir Res"},{"issue":"12","key":"10.1016\/j.chest.2020.12.027_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0081564","article-title":"Mycobacterium tuberculosis specific CD8(+) T\u00a0cells rapidly decline with antituberculosis treatment","volume":"8","author":"Nyendak","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.chest.2020.12.027_bib28","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/1040638718824074","article-title":"Distribution and expression of ESAT-6 and CFP-10 in non-tuberculous mycobacteria isolated from lymph nodes of slaughtered cattle in Switzerland","volume":"31","author":"Scherrer","year":"2019","journal-title":"J\u00a0Vet Diagn Invest"},{"issue":"1","key":"10.1016\/j.chest.2020.12.027_bib29","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.TNMI7-0011-2016","article-title":"Mycobacterium kansasii","volume":"5","author":"Johnston","year":"2017","journal-title":"Microbiol Spectr"},{"issue":"15","key":"10.1016\/j.chest.2020.12.027_bib30","doi-asserted-by":"crossref","first-page":"3969","DOI":"10.1073\/pnas.1621360114","article-title":"Quantification of circulating Mycobacterium tuberculosis antigen peptides allows rapid diagnosis of active disease and treatment monitoring","volume":"114","author":"Liu","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"10.1016\/j.chest.2020.12.027_bib31","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/intimm\/dxq429","article-title":"Increased IgG1, IFN-gamma, TNF-alpha and IL-6 responses to Mycobacterium tuberculosis antigens in patients with tuberculosis are lower after chemotherapy","volume":"22","author":"Mattos","year":"2010","journal-title":"Int Immunol"},{"issue":"2","key":"10.1016\/j.chest.2020.12.027_bib32","first-page":"132","article-title":"Mycobacteria-specific cytokine responses as correlates of treatment response in active and latent tuberculosis","volume":"75","author":"Clifford","year":"2017","journal-title":"J\u00a0Infect"},{"issue":"7","key":"10.1016\/j.chest.2020.12.027_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0219470","article-title":"Barriers to access and adherence to tuberculosis services, as perceived by patients: a qualitative study in Mozambique","volume":"14","author":"De Schacht","year":"2019","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.chest.2020.12.027_bib34","doi-asserted-by":"crossref","first-page":"1801030","DOI":"10.1183\/13993003.01030-2018","article-title":"Interventions to improve retention-in-care and treatment adherence among patients with drug-resistant tuberculosis: a systematic review","volume":"53","author":"Law","year":"2019","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.chest.2020.12.027_bib35","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-019287","article-title":"Determinants of non-adherence to treatment for tuberculosis in high-income and middle-income settings: a systematic review protocol","volume":"8","author":"Wurie","year":"2018","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.chest.2020.12.027_bib36","first-page":"148","article-title":"Respiratory functional changes in pulmonary tuberculosis [in Romanian]","volume":"62","author":"Apostu","year":"2013","journal-title":"Pneumologia"},{"issue":"1","key":"10.1016\/j.chest.2020.12.027_bib37","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1183\/09031936.00227014","article-title":"Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis","volume":"46","author":"Vorselaars","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.chest.2020.12.027_bib38","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/j.rmed.2018.02.009","article-title":"Efficacy and safety of infliximab biosimilar Inflectra\u00ae in severe sarcoidosis","volume":"138S","author":"Schimmelpennink","year":"2018","journal-title":"Respir Med"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001236922035515X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001236922035515X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T08:29:54Z","timestamp":1757924994000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001236922035515X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S001236922035515X"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2020.12.027","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II Investigation of the Efficacy of Antimycobacterial Therapy in Chronic Pulmonary Sarcoidosis","name":"articletitle","label":"Article Title"},{"value":"Chest","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2020.12.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc under license from the American College of Chest Physicians.","name":"copyright","label":"Copyright"}]}}